Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

85P - The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on patients with stage I non-small cell lung cancer harboring sensitive EGFR mutations


31 Mar 2023


Poster Display session


Yu Jiang


Journal of Thoracic Oncology (2023) 18 (4S): S89-S100.


Y. Jiang1, Y. Lin1, W. Fu2, R. Zhong3, Q. He4, J. He5, W. Liang3

Author affiliations

  • 1 Guangzhou/CN
  • 2 The 1st Affiliated Hospital of Guangzhou Medical University, Guangzhou/CN
  • 3 State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou/CN
  • 4 The 1st Affiliated Hospital of Guangzhou Medical University, 510000 - Guangzhou/CN
  • 5 The First Affiliated Hospital of Guangzhou Medical University, Guangzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 85P


Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA NSCLC, after surgical resection remains unclear. We aimed to compare the effect of EGFR-TKIs versus observation on survival in such patients by incorporating an established 14-gene molecular assay for risk stratification.


From March 2013 to February 2019, completely resected stage I (8th TNM staging for NSCLC) non-squamous NSCLC patients with sensitive EGFR mutation, who were followed up for at least five years, were included. Patients with eligible samples for molecular risk stratification were subjected to the 14-gene prognostic assay. The 5-year disease-free survival (DFS) rates between patients who underwent EGFR-TKI treatment and observation were compared using Kaplan-Meier analysis and Cox regression with a propensity score matching (PSM). The results of the 14-gene assay were used to further stratify the effect of EGFR-TKIs in different risk groups.


A total of 227 stage I NSCLC patients were enrolled, with 110 in stage IA and 117 in stage IB. After PSM, a matched cohort with 96 (48:48) patients was generated. The median duration of follow-up was 78.9 months. In the overall population, patients with adjuvant EGFR-TKIs had better 5-year DFS rates than those in the observation group (97.9% vs. 81.3%; P = 0.008). For patients with IA NSCLC, those receiving EGFR-TKIs had favorable 5-year DFS rates (100.0% vs. 88.2%; P = 0.485); a same trend was obtained from IB group (96.8% vs. 77.4%; P = 0.053). The 14-gene assay was performed in 71 patients. In the observation group, patients in high-risk group had inferior DFS compared with those with intermediate (HR = 3.48, P = 0.192) and low-risk group (HR = 12.50, P = 0.024). Among intermediate-high-risk patients, EGFR-TKIs were associated with a significant trend in 5-year DFS rate benefit compared to observation (95.2% vs. 68.8%; P = 0.066), while there was no difference among low-risk group (100.0% vs. 89.5%; P = 0.492).


We showed that adjuvant EGFR-TKI might improve DFS of EGFR-mutated stage IA and IB NSCLC, and the 14-gene molecular assay could help enrich those benefits from treatment. This modality merits prospective interventional trials in the future.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.